spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Lucentis 

 HSMN NewsFeed - 24 Jul 2024
Beacon Therapeutics Appoints Lance Baldo, MD as Chief Executive Officer and Thomas Biancardi as Chief Financial Officer
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 14 Feb 2023
KeifeRx Appoints Garrett Vygantas, MD, MBA, to Board of Directors
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 4 Apr 2019
DelMar Pharmaceuticals Welcomes Dr. John de Groot, Chairman, ad interim of the Department of Neuro-Oncology at MD Anderson Cancer Center, as founding member of the Company's Scientific Advisory Board
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 20 Nov 2018
Oculis Strengthens its Global Clinical and Business Development Capabilities Through Strategic Appointments to Senior Management Team
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 24 Sep 2018
Oculis Appoints World-renowned Ophthalmology Specialist
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 25 Jun 2018
DelMar Pharmaceuticals Appoints World-Renowned Molecular Biologist Dr. Napoleone Ferrara to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Feb 2018
Phase II Data Support Potential for Novel Anti-VEGF/Anti-Angiopoietin-2 Bispecific Antibody, RG7716, for People With Diabetic Macular Edema
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 12 Dec 2016
Ophthotech Announces Results from Pivotal Phase 3 Trials of Fovista(R) in Wet Age-Related Macular Degeneration
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 11 Oct 2016
FDA Grants Priority Review to Genentech’s Lucentis(R) (Ranibizumab Injection) Supplemental Biologics License Application for Myopic Choroidal Neovascularization
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 8 Aug 2016
Apellis Pharmaceuticals Announces Appointment of Dr. Robert Kim as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 May 2016
Notal Vision Announces Appointment of Quinton Oswald as Chief Executive Officer
Devices Monitoring Ophthalmology Personnel
 HSMN NewsFeed - 5 Jan 2016
Glenn P. Sblendorio to Join Ophthotech as Executive Vice President, Chief Operating Officer and Chief Financial Officer
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 17 Oct 2014
EYLEA(R) (aflibercept) Injection Demonstrates Significantly Greater Gains in Visual Acuity than Both Bevacizumab and Ranibizumab in NIH-Sponsored Diabetic Macular Edema Study
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 30 Jun 2014
Allergan Announces R&D Pipeline Update and U.S. FDA Approval; Company to Host Conference Call Today, Monday, June 30th at 10:30 AM ET
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 3 Feb 2014
PDL BioPharma Announces Agreement with Genentech and Roche to Settle Litigation and Arbitration
Biopharmaceuticals Litigation
 HSMN NewsFeed - 29 May 2013
Ophthotech Raises $175 Million to Finance the Pivotal Phase 3 Program for Fovista(TM) Anti-PDGF Combination Therapy in Wet AMD
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 26 Jul 2012
Endocyte Appoints David Meek to Newly Created Position of Chief Commercial Officer
Biopharmaceuticals Personalized Medicine Personnel
 HSMN NewsFeed - 26 Jul 2012
FDA Advisory Committee Unanimously Recommends Approval of Lucentis for Treatment of Diabetic Macular Edema (DME)
Biopharmaceuticals Ophthalmology Endocrinology FDA
 HSMN NewsFeed - 14 May 2012
FDA Grants Fast Track Designation to Ohr Pharmaceutical's Squalamine Eye Drops for the Treatment of Wet-AMD
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 3 May 2012
Oraya Therapeutics Achieves Successful INTREPID Study Outcomes with a Non-Invasive Radiation Therapy for Wet AMD
Devices Ophthalmology
 HSMN NewsFeed - 8 Mar 2012
Regeneron and Bayer Announce Approval of EYLEA(R) (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration in Australia
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 7 Dec 2011
Icon Appoints Murahashi Vice President, Clinical Development
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 7 Jun 2011
XOMA Appoints Paul Rubin, M.D. as Vice President and Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Mar 2011
Second Lucentis Phase III Study Meets Primary Endpoint for Improved Vision in Patients with Diabetic Macular Edema (DME)
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 11 Feb 2011
Lucentis Phase III Study Meets Primary Endpoint for Improving Vision in Patients With Diabetic Macular Edema (DME)
Biopharmaceuticals Endocrinology Ophthalmology
 HSMN NewsFeed - 26 Aug 2010
XOMA Appoints Jack L. Wyszomierski to Its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Aug 2010
Inspire Names Dr. Charles Johnson as Executive Vice President of Research and Development and Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Jun 2010
QLT Announces Final Results From Its RADICAL Study Evaluating Verteporfin PDT (Visudyne(R)) Combination Therapy in Exudative AMD
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 15 Dec 2009
Ophthotech Raises $30 Million in Series B Financing
Biopharmaceuticals Ophthalmology Venture Capital
 HSMN NewsFeed - 9 Dec 2009
6-month results from EVEREST study evaluating Visudyne(R) therapy in patients with polypoidal choroidal vasculopathy
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 17 Nov 2009
XOMA Appoints Jim Neal Vice President of Business Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Oct 2009
Peregrine Pharmaceuticals Appoints Former Genentech Senior Executive Dr. Robert Garnick as Head of Regulatory Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Oct 2009
XOMA Appoints Susan Kramer, Dr. P.H. Vice President of Project and Alliance Management
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Oct 2009
SurModics Enters Ophthalmic License and Development Agreement with Roche and Genentech
Biopharmaceuticals Ophthalmology Drug Delivery Licensing
 HSMN NewsFeed - 20 Aug 2009
Sutro Biopharma Announces Additions to Board of Directors and Senior Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Jul 2009
Second Phase III Study Showed Lucentis Improved Vision in Patients With Retinal Vein Occlusion
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 15 Jun 2009
QLT announces 12-month results from Novartis sponsored MONT BLANC study evaluating standard-fluence Visudyne(R) combination therapy
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 15 Jan 2009
XOMA Announces Workforce Reduction
Biopharmaceuticals
 HSMN NewsFeed - 26 Sep 2008
ISTA Pharmaceuticals Receives $65 Million Funding Commitment
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 30 Aug 2008
Monoclonal Antibody Sales to Almost Double in Coming Years
Biopharmaceuticals
 HSMN NewsFeed - 19 Aug 2008
Regeneron and Bayer HealthCare Announce VEGF Trap-Eye Achieved Durable Improvement in Vision over 52 Weeks in a Phase 2 Study in Patients with Age-Related Macular Degeneration
Biopharmaceuticals Opthalmology
 HSMN NewsFeed - 8 May 2008
Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 28 Apr 2008
Regeneron and Bayer HealthCare Announce Encouraging 32-Week Follow-Up Results from a Phase 2 Study of VEGF Trap-Eye in Age-Related Macular Degeneration
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 17 Apr 2008
FDA Grants NeoVista's Request to Expand CABERNET Trial to 30 Sites in the U.S.
Devices Ophthalmology FDA
 HSMN NewsFeed - 7 Apr 2008
Novartis to further strengthen its healthcare portfolio by acquiring 25% stake in Alcon from Nestlé with right to take over majority ownership of the world leader in eye care
Biopharmaceuticals Ophthalmology Mergers & Acquisitions
 HSMN NewsFeed - 28 Mar 2008
NeoVista Presents One Year Data on Novel Wet AMD Therapy at Macula Society
Devices Ophthalmology
 HSMN NewsFeed - 10 Mar 2008
XOMA Appoints Mary L. Anderson as Vice President of Business Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Nov 2007
First European Patient Treated in CABERNET Trial With Novel Treatment for Wet AMD
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 19 Nov 2007
APT Pharmaceuticals Expands Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Oct 2007
Steven Engle Appointed Chairman of XOMA
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Aug 2007
XOMA Appoints Steven B. Engle President, Chief Executive Officer and Director
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Aug 2007
Regeneron and Bayer HealthCare Initiate Phase 3 Global Development Program For VEGF Trap-Eye In Wet Age-Related Macular Degeneration (AMD)
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 9 May 2007
VEGF Trap-Eye Phase 2 Wet AMD Results Reported at ARVO Annual Meeting
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 12 Apr 2007
XOMA Announces Clinical Trial Plans for XOMA 052 in Type 2 Diabetes
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 10 Apr 2007
Trellis Bioscience Names Bruce Keyt, Ph.D. as Chief Technology Officer and Vice President of Research
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Mar 2007
Acuity Pharmaceuticals and Froptix Corporation Agree to Mergers with Public Shell; New Company to Develop and Market Drugs for Disorders of the Eye
Biopharmaceuticals Ophthalmology Mergers & Acquisitions
 HSMN NewsFeed - 26 Feb 2007
XOMA Announces Planned Retirement of Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Nov 2006
Carl Zeiss Meditec Announces Installation of 6000th Stratus OCT
Devices Ophthalmology
 HSMN NewsFeed - 4 Oct 2006
New England Journal of Medicine Publishes Data From Lucentis Pivotal Phase III Studies in Wet Age-Related Macular Degeneration
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 6 Sep 2006
XOMA's NEUPREX(R) Granted Orphan Status in Europe
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 30 Jun 2006
FDA Approves LUCENTIS for the Treatment of Wet Age-Related Macular Degeneration
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 30 Jun 2006
OXiGENE'S Board of Directors Names Experienced Biotech Executive, Richard Chin, M.D., as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Jun 2006
Preliminary Results from a Phase IIIb Study Showed Patients With Wet AMD Treated With Lucentis Quarterly Experienced a 16-Letter Benefit Over the Control Group at One Year
Biopharmaceuticals Ophthalmology
Return to NewsFeed  

 Additional items found! 28

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 28 additional stories matching:
Lucentis
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.